The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics
- PMID: 34873156
- PMCID: PMC8648877
- DOI: 10.1038/s41467-021-27341-1
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics
Abstract
Histology plays an essential role in therapeutic decision-making for lung cancer patients. However, the molecular determinants of lung cancer histology are largely unknown. We conduct whole-exome sequencing and microarray profiling on 19 micro-dissected tumor regions of different histologic subtypes from 9 patients with lung cancers of mixed histology. A median of 68.9% of point mutations and 83% of copy number aberrations are shared between different histologic components within the same tumors. Furthermore, different histologic components within the tumors demonstrate similar subclonal architecture. On the other hand, transcriptomic profiling reveals shared pathways between the same histologic subtypes from different patients, which is supported by the analyses of the transcriptomic data from 141 cell lines and 343 lung cancers of different histologic subtypes. These data derived from mixed histologic subtypes in the setting of identical genetic background and exposure history support that the histologic fate of lung cancer cells is associated with transcriptomic features rather than the genomic profiles in most tumors.
© 2021. The Author(s).
Conflict of interest statement
Jianjun Zhang reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work. J. V. H. reports research funding from AstraZeneca, GlaxoSmithKline, and Spectrum; consultant fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, EMD Serono, Foundation Medicine, Hengrui Therapeutics, Genentech, GSK, Guardant Health, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics, Spectrum, and Takeda; licensing fees from Spectrum. B. S. reports consultant fees from BMS. M. V. N. reports research funding from Mirati, Novartis, Checkmate, Ziopharm, AstraZeneca, Pfizer, and Genentech; consultant fees from Mirati, Merck/MSD. The other authors declare neither financial nor non-financial interests in the submitted work.
Figures





Similar articles
-
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.Clin Cancer Res. 2016 Jul 15;22(14):3618-29. doi: 10.1158/1078-0432.CCR-15-2946. Epub 2016 Mar 9. Clin Cancer Res. 2016. PMID: 26960398 Free PMC article.
-
Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma.J Thorac Oncol. 2009 Feb;4(2):227-39. doi: 10.1097/JTO.0b013e3181952678. J Thorac Oncol. 2009. PMID: 19179901
-
Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer.J Thorac Oncol. 2011 Nov;6(11):1833-40. doi: 10.1097/JTO.0b013e3182295917. J Thorac Oncol. 2011. PMID: 22011649
-
Genomic architecture of lung cancers.Curr Opin Oncol. 2016 Jan;28(1):52-7. doi: 10.1097/CCO.0000000000000251. Curr Opin Oncol. 2016. PMID: 26569422 Review.
-
Expression profiling and lung cancer development.Proc Am Thorac Soc. 2007 Jan;4(1):127-32. doi: 10.1513/pats.200607-143JG. Proc Am Thorac Soc. 2007. PMID: 17202302 Review.
Cited by
-
Novel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment.Cancers (Basel). 2024 Dec 12;16(24):4145. doi: 10.3390/cancers16244145. Cancers (Basel). 2024. PMID: 39766047 Free PMC article. Review.
-
Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer.Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2500019122. doi: 10.1073/pnas.2500019122. Epub 2025 Jun 11. Proc Natl Acad Sci U S A. 2025. PMID: 40498460
-
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.Cancer Cell. 2024 Feb 12;42(2):225-237.e5. doi: 10.1016/j.ccell.2024.01.001. Epub 2024 Jan 25. Cancer Cell. 2024. PMID: 38278149 Free PMC article.
-
Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma.Transl Lung Cancer Res. 2024 Sep 30;13(9):2222-2235. doi: 10.21037/tlcr-24-292. Epub 2024 Sep 27. Transl Lung Cancer Res. 2024. PMID: 39430332 Free PMC article.
-
Antitumor Effect of mTOR1/2 Dual Inhibitor AZD8055 in Canine Pulmonary Carcinoma.Cancers (Basel). 2025 Jun 14;17(12):1991. doi: 10.3390/cancers17121991. Cancers (Basel). 2025. PMID: 40563640 Free PMC article.
References
-
- Grilley-Olson JE, et al. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Arch. Pathol. Lab. Med. 2013;137:32–40. doi: 10.5858/arpa.2012-0033-OA. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases